Study shows better option for treatment of inoperable anal cancer
Updated:5 years, 4 months ago
Updated:5 years, 4 months ago
New Delhi, June 26 (ANI): A new study has suggested that people with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered. The results from an international trial, published by the Journal of Clinical Oncology, suggest that carboplatin-paclitaxel become the standard of care for anal cancer, a rare disease that accounts for less than 3 per cent of all gastrointestinal malignancies. The InterAAct trial compared carboplatin-paclitaxel with cisplatin plus 5-flourouracil (5FU). The overall survival of patients enrolled on the carboplatin-paclitaxel arm of the clinical trial was 20 months compared to 12.3 months for those on the cisplatin-5FU arm. Carboplatin-paclitaxel was associated with significantly less adverse effects (36 per cent) compared to cisplatin-5FU (62 per cent). Patients with inoperable anal cancer have a five-year survival rate of approximately 30 per cent.
Updated:4 years, 9 months ago
Pan-India dry run for COVID vaccine tomorrow: Harsh Vardhan
Updated:4 years, 9 months ago
PM Modi joins world leaders in condemning US Capitol siege
Updated:4 years, 10 months ago
Indo-Japan Samvad: Buddha’s message spread out from India to world, says PM Modi
Updated:4 years, 10 months ago
Centre preparing with states for past 4 months for COVID-19 vaccination: Harsh Vardhan
Updated:4 years, 10 months ago
In Jan, India may be in position to give 1st COVID vaccine shot: Harsh Vardhan
Updated:4 years, 10 months ago
Worst is over but still need to be cautious: Health Minister on COVID-19 cases in India